Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/24/2025

Management of Persistent Urogenital Symptoms and Vaginal Dryness in Postmenopausal Women on HRT

Current Regimen Assessment and Recommendations

  • The National Comprehensive Cancer Network recommends that postmenopausal women on hormone replacement therapy (HRT) with persistent urogenital symptoms and vaginal dryness consider adding local vaginal estrogen therapy to their current regimen, as systemic estrogen may not adequately address localized vaginal symptoms 1
  • Localized urogenital symptoms can persist in postmenopausal women despite adequate systemic hormone levels due to vaginal tissue-specific estrogen requirements, highlighting the need for targeted local therapy 2
  • The American College of Obstetricians and Gynecologists supports the use of low-dose vaginal estrogen as an effective treatment for vaginal dryness leading to sexual dysfunction, and for symptoms such as itching, discomfort, and painful intercourse in postmenopausal women 1
  • Local vaginal estrogen preparations, including rings, suppositories, and creams, have demonstrated effectiveness in managing urogenital symptoms in postmenopausal women, according to the National Comprehensive Cancer Network 3

Supportive Measures

  • Regular use of vaginal moisturizers (3-5 times weekly) and lubricants during sexual activity is recommended to complement hormonal therapy in postmenopausal women with urogenital symptoms, as suggested by the Journal of Clinical Oncology 4
  • Pelvic floor physical therapy should be considered for postmenopausal women with signs of pelvic floor dysfunction contributing to urogenital symptoms, based on guidelines from the National Comprehensive Cancer Network and the Journal of Clinical Oncology 2, 5

Monitoring and Follow-up

  • The National Comprehensive Cancer Network recommends assessing response to therapy after 4-6 weeks of treatment in postmenopausal women with urogenital symptoms, and considering adjustments to the treatment plan as needed 6
  • If symptoms persist despite local therapy, increasing the systemic estradiol patch dose may be considered, although this is less effective for vaginal symptoms than direct vaginal application, according to the Journal of Clinical Oncology 7
  • Monitoring for adverse effects of combined systemic and local estrogen therapy is essential, although the risk of systemic effects from low-dose vaginal estrogen is minimal, as noted by the National Comprehensive Cancer Network 1

Vaginal Estrogen Therapy for Urogenital Symptoms

Introduction to Vaginal Estrogen Therapy

  • The European Association of Urology gives a STRONG recommendation to use vaginal estrogen replacement in postmenopausal women to prevent recurrent UTI 8
  • The American Urological Association, Canadian Urological Association, and Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction provide a Moderate Recommendation (Grade B evidence) that vaginal estrogen therapy should be recommended to all peri- and postmenopausal women with recurrent UTIs to reduce the risk of future infections 9, 10

Rationale for Vaginal Estrogen

  • Vaginal tissues require direct local estrogen application to restore the vaginal epithelium, normalize pH, and maintain protective Lactobacillus species that prevent UTIs 11
  • Systemic estrogen does not effectively address vaginal tissue-specific estrogen requirements, even when systemic hormone levels are adequate, according to the Journal of Urology 9, 10

Efficacy and Safety of Vaginal Estrogen

  • Vaginal estrogen works by reducing vaginal atrophy, restoring the vaginal microbiome, and decreasing UTI frequency through mechanisms that systemic estrogen cannot achieve 11
  • Vaginal estrogen has minimal systemic absorption and carries very low systemic risks 9, 10, 11
  • No concerning safety signals regarding stroke, venous thromboembolism, invasive breast cancer, colorectal cancer, or endometrial cancer were identified in large prospective cohort studies of over 45,000 women using topical estrogen 11

Treatment Approach

  • Women already on systemic estrogen therapy can and should still be placed on vaginal estrogen therapy for urogenital symptoms—there is no substantially increased risk of adverse events from combining both 9, 10
  • Common formulations include estradiol vaginal tablets, estradiol vaginal rings, or estrogen-based vaginal creams 9, 10

Important Considerations

  • Do not confuse systemic estrogen therapy with vaginal estrogen therapy—oral or transdermal systemic estrogen has not been shown to reduce UTI risk and does not effectively treat vaginal atrophy 9, 10

REFERENCES

1

nccn guidelines® insights: survivorship, version 2.2024. [LINK]

Journal of the National Comprehensive Cancer Network : JNCCN, 2024

3

survivorship, version 2.2017, nccn clinical practice guidelines in oncology. [LINK]

Journal of the National Comprehensive Cancer Network : JNCCN, 2017

5

vulvar cancer, version 3.2024, nccn clinical practice guidelines in oncology. [LINK]

Journal of the National Comprehensive Cancer Network : JNCCN, 2024